The in vitro influences of neurotensin on the motility characteristics of human U373 glioblastoma cells
Introduction
The World Health Organization (WHO) classifies astrocytic tumours into four histopathological grades according to their levels of malignancy [1] . Grade I includes benign tumours like pilocytic astrocytomas and subependymal giant cell astrocytomas, Grade II tumours are associated with a rather good prognosis of 10-20 years' survival after the initial diagnosis while Grades III (anaplastic astrocytomas) and IV (glioblastomas) are highly malignant tumours associated with dismal prognoses [2] . Indeed, about 90% of glioblastoma patients die in the year following the initial diagnosis of their tumours. The malignant nature of astrocytic tumours is directly related to their ability to diffusely invade the brain parenchyma, so making complete surgical resections impossible [2] . Vari-ous neuropeptides (for example, angiotensin, bombesin, bradykinin, cholecystokinin, endothelin, gastrin and neurotensin, etc.) are able to modify the biological behaviour of tumour astrocytes [3] . We accordingly show that cholecystokinin/gastrin-related peptides modify both the cell proliferation [4, 5] and the migratory [6] [7] [8] characteristics of glioblastoma cells. Astrocytic tumours also express neurotensin receptors (NTRs) [9] , and we have previously shown that neurotensin is able to significantly modify the proliferation rates of various human astrocytic tumour cell lines [10] .
The invasive abilities of individual tumour astrocytes mainly depend on their migratory potential, which is related to three processes, that is, their adhesion to extracellular matrix (ECM) components and other cells, their motility involving the dynamics of the cell cytoskeleton, and their invasive ability that requires the degradation of matrix proteins by proteolytic enzymes. To migrate, glioma cells secrete ECM components that facilitate their motility [11] [12] [13] . Laminin -a pro-adhesive ECM component -is ubiquitously secreted by glioma cells [11, 12, 14] ; it is upregulated in human high-grade diffuse astrocytic tumours [12, 14] and strongly stimulates glioma cell motility in vitro [15] . The major steps involved in cell movement are the extension of a leading edge protrusion or lamellipodium, the establishment of new adhesion sites at the leading edge, the contraction of the cell body and the release of the adhesion at the rear [16] . All these steps involve the assembly, the disassembly or reorganization of the actin cytoskeleton. Most neuropeptides, including neurotensin, function biologically through binding to specific G-protein-coupled receptors (GPCRs) on the surface of the target cells [17] , and this binding to GPCRs in turn induces profound modifications in the organization of the actin cytoskeleton [18] . Small GTPases of the Rho family (that is, the Rho-GTPases), including RhoA, Cdc42 and Rac1, play a pivotal role in regulating the signalling pathways which are activated by the binding of neuropeptides to GPCRs [18] and which are relevant to cell migration [16] . These GTPases act as molecular switches to control the signal transduction pathways by cycling between a GDP-bound inactive form and a GTP-bound active one [16] . In their GTP-bound state, they interact with downstream targets (effectors) to elicit a variety of intracellular responses, including the reorganization of the actin cytoskeleton. While RhoA regulates the assembly of contractile acto-myosin filaments, Rac1 and Cdc42 regulate the polymerization of actin to form peripheral lamellipodial and filopodial protrusions respectively [19] . In addition, these three GTPases promote the assembly of integrin-based matrix adhesion complexes [20] [21] [22] .
The aim of the present work is to characterize the effects of neurotensin on the motility characteristics of the U373 model, an aggressive human glioma of astrocytic origins [23] [24] [25] . Neurotensin is widely distributed in the central nervous system (CNS) and its peripheral tissue, and its actions are mediated by specific receptors. Of the three subtypes of NTRs cloned, NTR1 and NTR2 belong to the family of GPCRs while NTR3 is a new type of neuropeptide receptor in the form of a 95-kDa protein (identical to gp95/sortilin) with a single transmembrane domain [9, [26] [27] [28] . Different studies of rat CNS have revealed a widespread expression of these NTRs throughout the adult brain [29] [30] [31] . We made use of an RT-PCR approach to characterize at mRNA level the type of NTR present in U373 glioblastoma cells. In addition, we investigated the influence of neurotensin on the levels of activity of RhoA, Cdc42 and Rac1, and on the organization of the actin cytoskeleton. Finally, we made use of two distinct cell migration assays to characterize the influence of neurotensin on the motility features of U373 cells cultured on plastic and laminin.
Materials and methods

Cell culture
The human glioma cell line U373, whose unique astrocytic origin we had previously confirmed [23, 24] , was obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA; HTB14). The cells were maintained as monolayers in a specific medium, as detailed elsewhere [4, 24] .
Compounds
Neurotensin and laminin (from the basement membrane of Engelbreth-Holm-Swarm murine sarcoma) were purchased from Sigma (St Louis, MO, USA). Culture dishes were coated with laminin by allowing a stock solution (0.833 ng/ml) to dry on the surface for one night at room temperature. The dishes were rinsed twice with sterile phosphate-buffered saline (PBS, GibcoBRL, InvitrogenSA, Merelbeke, Belgium) just before the plating of the cells.
Analysis of NTRs mRNA expression
The U373 tumour cells were grown to subconfluence in plastic Falcon dishes, and total RNA was prepared with the High Pure RNA Isolation Kit (Roche Diagnostics, Vilvoorde, Belgium) according to the manufacturer's recommendations. The quantities of RNA extracted were measured with the Ribogreen Kit (Molecular Probes, Eugene, OR, USA). A second quantification was carried out by means of a spectrophotometer (at 260 and 280 nm), which also enabled the sample quality to be checked (by means of the 260/280 ratio). Ten nanograms of total RNA were reverse-transcribed and amplified using the GeneAmp Thermostable rTth Reverse Transcriptase RNA PCR Kit (Perkin-Elmer, Boston, MA, USA) and specific pairs of primers (InvitrogenSA). The sequence of the primers, the numbers of PCR cycles and the size of the RT-PCR products are described in Table 1 . These products were analysed on 10% polyacrylamide gels. After staining with GelStar dye (FMC BioProducts, Rockland, ME, USA) the signals were quantified using Fluor-S MultiImager (Bio-Rad, Hercules, CA, USA). The amplification of the 28S rRNA was carried out to check each RNA sample analysed (data not shown). The analysis of the mRNA expression or each NTR included a negative control (that is, water) which evidenced no band (data not shown).
Pull-down assays
Active GTP-bound forms of the three Rho GTPases were measured on U373 cells cultured on plastic as described by Ren et al . [32] and Sander et al . [33] . Cells were chilled on ice and lysed in an ice-cold buffer (50 mM Tris pH 7.2 containing 1% Triton X-100, 150 mM NaCl, 10 mM MgCl 2 , 10 µ g/ml each of leupeptin and aprotinin, and 0.1 mM PMSF). The cell lysates were clarified by centrifugation at 13 000 g at 4 ° C for 8 min. Aliquots of the supernatants were denatured in SDS-PAGE lysis buffer (v/v) in order to measure the total amount of the Rho GTPases by Western blotting. For the pull-down assays the supernatants were incubated at 4 ° C for 30 min with 30 µ g of a fusion protein between glutathione-S-transferase (GST) and either the PBD domain of the Rac1-and Cdc42-effector PAK, or the RBD domain of the RhoA-effector Rhotekin, linked to glutathione-Sepharose beads (Amersham Biosciences, Buckinghamshire, UK). The beads were washed four times in lysis buffer and denaturated in SDS-PAGE buffer. The total and activated proteins were analysed in parallel by Western blotting with mouse monoclonal antibodies against RhoA, Rac1 or Cdc42. The anti-RhoA antibody (1/400) was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA), the anti-Rac1 (1/1000) from Upstate Biotechnology (Lake Placid, NY, USA), and the anti-Cdc42 (1/250) from Transduction Laboratories (San Diego, CA, USA).
Analysis of the actin cytoskeleton
Fluorescent phallacidin conjugated with Alexa Fluor® 488 fluorochrome (Molecular Probes Inc., Eugene, OR, USA) was used to label the fibrillar actin, and Alexa Fluor® 594-conjugated DNAseI (Molecular Probes Inc.) to stain the globular actin. The cells were cultured 48 h on glass coverslips prior to the fluorescence staining, as described elsewhere [8] .
Cell motility measurements by means of computer-assisted videomicroscopy
We developed and implemented a specialized software package on computers connected to phase-contrast videomicroscopy systems placed in 37 ° C-heated incubators [6, 34] . This package enables the trajectories of individual cells to be established and quantitatively analysed ( Figure 1 A,B ). The cell-tracking algorithm is based on a model-based approach using an adapted mean-shift process which enables each cell to be tracked efficiently for hours and which is able to produce detailed descriptions of individual cell trajectories [34] . We validated this software on several cell culture experiments by means of comparisons with human-controlled analyses [34] . The images were acquired and stored as previously described [6] . Briefly, they were obtained under a phase-contrast microscope (Olympus, Aartselaan, Belgium; model IX50, with a 10 : 1 magnification ratio) with a CCD video camera (Hitachi Denshi, Tokyo, Japan; model KP-M1E/K-S10) coupled to an acquisition board (32-bits Matrix Vision PC-GRAB-GI frame grabber). Image acquisition was effected every 4 min over a number of hours (typically 24 h, that is, 360 images). The dimensions of the images were 700 × 500 pixels discretized into 256 grey levels (8 bits per pixel). The parameter used to characterize each cell trajectory was the Maximum Relative Distance from the point of Origin (MRDO). This refers to the greatest linear distance between the original position of a cell (at time = 0) and the farthest position reached by the cell in its trajectory (Figure 1 C ) . The MRDO is this maximum distance normalized by the observation time for the cell analysed (to be able to compare cell trajectories corresponding to different observation times). The neurotensin effects were evaluated in terms of the MRDO variable on particular and complete cell populations. This is illustrated in Figure 1 D , which shows how to identify a subpopulation of cells consisting of the 25% most motile ones (see the hatched vertical line) on the basis of the distribution of the MRDO values (the black bars).
Scratch wound assay
The U373 glioblastoma cells were grown to confluence in six well dishes. Scratch wounds were made by creating a linear decellularized region using a pipette tip (as illustrated in the Results ). The cells were washed twice with PBS before their incubation in culture medium with neurotensin (0.1, 10 and 1000 nM). The colonization of the wound by the U373 cells cultured in a serum-free medium or in a medium supplemented with 5% foetal bovine serum and in the presence or the absence (control) of neurotensin was analysed for 40 h (at different points of time).
Six fields of each of the three wounds analysed per condition were photographed 0, 15, 24 and 40 h after the neurotensin treatment. An algorithm developed in our 
Statistical analysis
Because the conditions for applying the parametric tests were not satisfied, we used nonparametric tests to compare independent groups of numerical data. Statistical comparisons between the multiple groups of cells were made by first carrying out the Kruskal-Wallis test (a nonparametric one-way analysis of variance). In cases where this test revealed significant differences, we investigated by means of the Mann-Whitney test whether any of the groups of treated cells differed from control. [35] . Figure 3 E shows that while neurotensin did not activate RhoA, it did activate Rac1 and Cdc42 in a time-dependent manner in the U373 tumour cells. The total levels of the Rho GTPases were not altered by the neurotensin treatment. These neurotensin-induced effects on the GTPases activity can at least partly explain the morphological and the cytoskeletal changes seen in the neurotensin-treated U373 tumour cells.
Results
NTR1, NTR2 and NTR3 mRNAs are expressed in human U373 glioblastoma cells
Neurotensin activates small GTPases in human U373 glioblastoma cells cultured on plastic and modifies their morphology and actin cytoskeleton organization
Neurotensin decreases the motility of U373 glioblastoma cells cultured on plastic in a serum-free medium
We used an in vitro wound-healing assay to determine the effect of neurotensin on U373 cell motility. Cell-free zones were created in confluent U373 monolayers by scratching off cells with a pipette tip. Each cell-free zone (see the black rectangle in Figure 4 A ) was approximately 250-300 µ m wide and several millimetres long. Time-lapse microscopy was used to analyse the recolonization rate of the cell-free zone (Figure 4 B ). Whereas neurotensin had no effect on 
Neurotensin decreases the motility of U373 glioblastoma cells cultured on plastic, but increases it when U373 cells are cultured on laminin
Computer-assisted phase-contrast microscopy (quantitative videomicroscopy) enabled the neurotensin-induced effects on the motility levels of the U373 glioblastoma cells to be quantitatively determined. These motility levels refer to the largest linear distance travelled by individual U373 cells per hour, and were obtained by computing the MRDO variable expressed in µ m/h. Figure 5 A shows that 0.1 and 10 nM neurotensin significantly decreased the levels of motility of the whole U373 cell population analysed ('100%') as well as of the 25% most motile U373 Figure 1 D ) when the cells were cultured on plastic. In sharp contrast, neurotensin increased the levels of motility of U373 glioblastoma cells cultured on laminin, with a more pronounced effect on the 25% most motile cells than on the U373 cell population as a whole (Figure 5 B ). Higher doses (that is, 1 µ M or higher) of neurotensin were not assayed in this cell motility assay because the wound-healing experiment had previously shown that pharmacological doses of neurotensin are no more effective on U373 cell motility ( Figure 4 ).
Discussion
Neurotensin is a tridecapeptide originally isolated from bovine hypothalamus and is located mainly in the CNS and the endocrinal cells (N cells) of the jejunal and ileal mucosa [27] . It is synthesized in the neurones in the whole of the brain [35] . In the CNS, neurotensin plays the role of a neurotransmitter and also acts as a neuromodulator of dopamine transmission and anterior pituitary hormone secretion [26] . It also has potent hypothermic and analgesic effects in the brain [26] . However, as emphasized by Reubi [26] , several lines of evidence also suggest that neurotensin plays a role in cancer. Several types of cancers, that is, small cell lung cancers, neuroblastomas, medulloblastomas, pancreatic cancers, colon cancers, meningiomas, Ewing's sarcomas, medullary thyroid carcinomas and astrocytomas, express NTRs [9, 26] . As also argued by Reubi [26] , an additional argument in favour of a role for neurotensin in cancer is the stimulation that this peptide exerts on the in vitro proliferation of tumour cell lines of various origins including the pancreas, the prostate and the lungs, and also of astrocytic tumour cell lines, as we have previously showed [10] . As is pointed out in the Introduction , the hallmark of malignant glioma development is their diffuse invasion of the brain parenchyma. This diffuse invasion is related to a myriad of individual tumour astrocytes migrating from the primary tumour site through the brain (possibly over long distances) [2] . Several studies have already pointed to a direct role played by neurotensin with respect to the migratory characteristics of a large set of cell types, including normal and tumour cells. For example, neurotensin modulates the locomotion of the neutrophils [37] , the lymphocytes [38] and the macrophages [39] that form part of the immune system, and also of microglia in the CNS [40] . Neurotensin stimulates intestinal wound healing [41] and angiogenesis [42] . It also modulates the migration features of cancer cells such as circulating malignant Sezary cells [43] . The data from the present study clearly indicate that whereas neurotensin decreases the levels of motility of human U373 glioblastoma cells cultured on plastic in a serum-free medium, no such effects are observed in culture media supplemented with 5% foetal bovine serum (which may contain either some traces of neurotensin or a number of factors activating the same signalling pathways as neurotensin). Moreover, while the neurotensin-induced decrease in U373 cell motility on plastic in a serum-free medium was observed at 0.1 and 10 nM, this effect was abolished at a higher dose (1 µ M). We observed very similar effects on the Hs683 model (data not shown), another aggressive human glioma of oligodendroglial origins [23, 24] . Most neuropeptides binding to GPCRs at physiological doses markedly modify the levels of expression and/or activity of a number of protein kinases C (PKCs) that play pivotal roles in the control of neuropeptide-mediated effects on cell prolifera- tion and/or migration [8, 18] . The lack of response to neuropeptides at pharmacological doses (in the micromolar range) may be related to a desensitization process of the PKCs, as it has already been observed for gastrin in several cell systems [5, 8, 44] . Indeed, we observed higher gastrin-induced modifications at tumour astrocyte cell proliferation [5] and migration [8] levels at a concentration of 10 nM rather than of 1 µM. A similar observation has been reported by Kimura et al. [44] , who noted that whereas micromolar concentrations of gastrincholecystokinin-related peptides inhibit PKC activity in acini, physiological concentrations of these peptides activate PKC-dependent signals.
Neurotensin signals its biological effects through NTR1, NTR2 and NTR3, the three different receptors identified to date which are widely expressed throughout the adult rat brain [29] [30] [31] . The NTR1 signalling pathway is well documented and includes Ca 2+ release from inositol 1,4,5 -triphosphate (IP 3 )-sensitive channels, the activation of mitogen-activated protein Rinases (MAPKs) via PKC, and the activation of AP-1 [26, 27] . In contrast, the signalling pathway that governs the interaction between neurotensin and NTR2 is a matter of controversy [26] . NTR2 seems to be involved in the analgesic effect of the peptide [26, 40] . The activation of NTR3 by neurotensin leads to the phosphorylation of both extracellular signalregulating kinases (ERK) 1/2 MAPK and Akt [40] . In addition, Martin et al. [45] provide biochemical evidence for the heterodimerization of NTR1 and NTR3 in the human HT-29 colon cancer cell line. NTR3 is the only NTR present in all the cancer cells on which neurotensin has a proliferative effect [40] . It is the only known receptor expressed in human C13NJ microglial cells, and the effect of neurotensin on the migration of these cells is preceded by a profound modification of the F-actin cytoskeleton, and particularly by the rapid formation of numerous cell filopodia [40] , a feature also observed here in U373 glioblastoma cells treated with neurotensin. In the case of other cell types (such as T lymphocytes and leukaemic Jurkat cells) it seems that only NTR1 is responsible for cell migration [42] . The present study shows that human U373 glioblastoma cells express NTR1, NTR2 and NTR3 at least at mRNA level, an expression pattern that we also evidenced in Hs683 glioma cells (data not shown). We cannot argue at present in favour of one or another specific receptor as the mediator of the neurotensin-induced effects on U373 cells. We are now developing an siRNA approach targeting each of these three NTRs to further characterize which one(s) is (are) involved in the neurotensin-induced effects on U373 cell motility. An intriguing finding of this study is the opposite effects of neurotensin on the motility of U373 cells cultured on plastic or laminin. These differences possibly reflect the engagement of different integrins depending of the culture support. With respect to this hypothesis, Ding et al. [46] reported that the physiological plateletderived growth factor (PDGF) stimulation of U-87 MG glioblastoma cells largely promotes αvβ3-mediated motility on vitronectin in contrast to the much lower migration rates observed on collagen or laminin (which engage different integrins). On the other hand, the levels of eosinophil chemotaxis induced by the plateletactivating factor were enhanced on laminin but not on vitronectin [47] . These data illustrate the profound impact of the cell-matrix interactions through the engagement of different integrins on the regulation of cell migration by soluble factors.
The present study reveals that the neurotensininduced effects observed in U373 cell motility are paralleled by profound modifications to the organization of the U373 actin cytoskeleton that could at least be partly explained by pronounced modifications at small GTPases activation level. Indeed, we observed that neurotensin is able to activate Rac1 and Cdc42 in U373 cells. These data agree with those reported by Zao et al. on human colonic epithelial cells overexpressing NTR1 [48] . The activation of Rac1 and Cdc42, which are known to stimulate the formation of actin-based membrane protrusions [19] , might thus explain the morphological changes observed in the U373 cells treated with neurotensin. The accumulation of fibrillar actin to form strong adhesion plaques at the tips of the filopodial protrusions might also explain the restricted motility of U373 cells induced by neurotensin.
In conclusion, our data strongly suggest that neurotensin is a neuropeptide capable of modulating tumour astrocyte migration into the brain parenchyma by acting on the actin cytoskeleton and its regulators at least.
